ArticleFrontiers in public health2023
Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Global and regional trends in multidrug- or rifampicin-resistant tuberculosis, 2000-2024 with forecasts to 2030: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Characteristics of Primary and acquired multidrug-resistant tuberculosis patients in West Java, Indonesia.IJID regions · 2026Article
- Article
- Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.Journal of thoracic disease · 2026Article
- Drug-resistant tuberculosis in Lishui, China: first-line drug resistance patterns, trends, and risk factors from a 10-year retrospective study (2015-2024).Frontiers in public health · 2026Article
- Risk factors and prediction modeling for drug-resistant tuberculosis in Shenzhen: a 9-year retrospective study.Frontiers in public health · 2026Article
- Risk factors and treatment outcomes of drug-resistant tuberculosis among patients attending Ndola Teaching Hospital, Zambia: a retrospective case-control study.The Pan African medical journal · 2026Article
- Trends and Characteristics of Drug-Resistant Tuberculosis: A Five-Year Study at a Major Specialized Hospital in Guizhou, China (2018-2023).Infection and drug resistance · 2026Article
- Epidemiological characteristics and risk factors analysis of multidrug-resistant tuberculosis among tuberculosis population in Huzhou City, Eastern China.Open life sciences · 2025Article
- Prevalence and epidemiological pattern of drug-resistant tuberculosis among migrant populations in Wenzhou City, China, 2014-2023: implications for public health strategies.Frontiers in public health · 2025Article
- Prediction of risk factors associated with the development of multidrug-resistant tuberculosis in patients with tuberculosis.Frontiers in public health · 2025Article
- Resistance characteristics of culture-positive tuberculosis from 2015 to 2022.Frontiers in public health · 2025Article
- Drug-resistant tuberculosis: a persistent global health concern.Nature reviews. Microbiology · 2024Review
- Regional differences of Mycobacterium tuberculosis complex infection and multidrug resistance epidemic in Luoyang.BMC infectious diseases · 2024Article
- Risk factors for multidrug-resistant tuberculosis: a predictive model study.Frontiers in medicine · 2024Article
- Analysis of epidemiological characteristics of extrapulmonary tuberculosis from South-Central China.Frontiers in public health · 2024Article
- Analysis on epidemiological and drug resistance characteristics of lymph node tuberculosis from Hunan province, China.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to examine the prevalence of multidrug-resistant tuberculosis (MDR-TB) in Luoyang, China, identify related risk factors, inform clinical practices, and establish standardized anti-tubercular treatment regimens. Methods: We conducted a retrospective analysis of high-resolution melting curve (HRM) data from 17,773 cases (2,748 of which were positive) between June 2019 and May 2022 to assess the prevalence of MDR-TB and to identify its associated risk factors. Results: Between June 2019 and May 2022, out of the 17,773 HRM results, 2,748 were HRM-positive, and 312 were MDR-TB cases. The detection rates for HRM-positive and MDR-TB were 17.0 and 12.1% for males, and 12.4 and 8.2% for females, respectively. The MDR-TB detection rate was higher in the urban areas (14.6%) than in the rural areas (10.6%) and more common among individuals under 51 years of age (14.1%) than those over 50 years of age (9.3%). Notably, the rate of detecting MDR-TB was 18.3% higher in new male patients than in new female patients, which was at 10.6%, and this difference was statistically significant ( Conclusion: Local TB infections are complex and diverse; therefore, more comprehensive monitoring methods are needed to curb the spread of MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.